2-Fluoroethamphetamine (2-FEA) is a novel stimulant substance of the amphetamine class that produces classical stimulant effects including stimulation, enhanced focus and euphoria when administered.
The exact effects of 2-FEA are not well-known by its users, with anecdotal reports suggesting only minimal activity and possible serotonergic qualities.
2-Fluoroethamphetamine (2-FEA) is a synthetic molecule from the substituted amphetamine class. Molecules of the amphetamine class contain a phenethylamine core featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain with an additional methyl substitution at Rα (i.e., amphetamines are alpha-methylated phenethylamines). 2-FEA contains an ethyl group bound to the terminal amine RN from the amphetamine core.
2-FEA is the N-ethylated homolog of 2-FA (2-fluoroamphetamine).
The effects of 2-FEA appear to be very subtle and difficult to characterize. Some reports suggest it is relatively mild and free of side effects in a similar fashion to 2-FA, while others note an increase in physical side effects or serotonergic activity reminiscent of 3-FEA.
2-FEA has not yet been formally studied to the same extent as traditional amphetamines. Currently, it is assumed that it most likely acts primarily as a triple reuptake inhibitor, and that it releases the neurotransmitters: serotonin, dopamine, and norepinephrine. 2-FEA likely creates it effects by acting as a releasing agent of said neurotransmitters and/or by binding to- and partially blocking the transporter proteins that normally clear substances from the synaptic cleft, after they have fulfilled their function of conducting a neural impulse.
3-Fluoroethamphetamine (also known as 3-FEA) is a novel ring-substituted amphetamine compound that produces a mixture of entactogenic and stimulant effects when administered. 3-FEA is structurally related to a series of designer fluorinated substituted amphetamines that originally included compounds such as for example 2-FA, 2-FMA, 3-FA, 4-FMA, 4-FA.
Like its parent compound 3-FA, the pharmacological, toxicological, and subjective effects of 3-FEA in humans have yet to be mapped out in detail. Anecdotal reports have characterized 3-FEA like a moderately potent serotonin-dominant triple monoamine releaser that produces a mixture of entactogenic and mild stimulating effects.
3-FEA, or 3-fluoroethamphetamine, is really a synthetic molecule of the amphetamine chemical class. Molecules of the amphetamine class include a phenethylamine core comprised of a phenyl ring bound to an amino (NH2) group through an ethyl chain substituted with a methyl group at Rα (i.e. amphetamines are alpha-methylated phenethylamines).
3-FEA is the 3-position fluorinated analog of ethylamphetamine (also known as ethamphetamine). It is also an analog of fenfluramine with the 3-trifluoromethyl group replaced having a 3-fluoro substituent.
Although 3-FEA has not been formally studied on the same level as traditional amphetamines, it really is currently assumed that like other substituted amphetamines with substitutions at similar positions, it most likely acts primarily being a triple reuptake inhibitor and/or releaser from the monoamine neurotransmitters serotonin, dopamine, and norepinephrine.
It has been demonstrated that compared to the unsubstituted ethylamphetamine, 3-fluoroethamphetamine is a weaker releaser of dopamine, but a stronger releaser of both serotonin and norepinephrine, producing the strongest reinforcing effects in animal studies out of a range of 3-substituted amphetamine derivatives tested, despite not being the most potent dopamine releaser.
This indicates that 3-FEA effectively increases the levels of all the three major monoamine neurotransmitters dopamine, norepinephrine, and serotonin in the brain by acting as a releasing agent of said neurotransmitters and/or by binding to and partially blocking the transporter proteins that normally clear those molecules from your synaptic cleft once they have fulfilled their function of conducting a neural impulse. This transporter blockade allows these molecules to accumulate within core synaptic regions of the brain to extra-endogenous levels, resulting in a combination of relaxing, stimulating, disinhibiting and euphoric effects associated with entactogenic substituted amphetamines such as MDMA or 4-FA.